Nā ʻōkuhi no ka hoʻohana "Trazhenty", hoʻonohonoho, analogues, kumukūʻai a me nā loiloi o nā maʻi maʻi

Hāʻawi ʻia ka lāʻau lapaʻau no ka hoʻohana ʻana ma nā pākeke me ke ʻano ke ʻano maʻi type 2.

Hāʻawi ʻia ka Monotherapy me ka lāʻau lapaʻau i ka hihia ke ʻae ʻia ka hoʻōla ʻana o ka hana pilikino a me ka nānā ʻana i ka meaʻai haʻahaʻa-kāʻai i ʻae ʻole i ka hoʻoponopono ʻana i ka pōʻai ʻai koko. Hiki ke lawe i kēia mau papa me ka intolerance i kekahi ʻano mea e like me ka metformin a i ʻole ka hele ʻana o nā contraindications i kāna hoʻokomo.

Hoʻohui maikaʻi ʻia (inā he maikaʻi ʻole ka mālama ʻana a me ka hoʻoikaika kino):

• E hui pū me nā metformin,
• Me ka sulfonylurea a me ka metformin
• Me ka insulin a me ka metformin.

Nā hoʻonohonoho hoʻonohonoho a hoʻokuʻu i nā palapala

Ma nā papa inoa Trazent, aia wale nō ka māhele ikaika e hōʻike ʻia ana e linagliptin, ʻo kāna mau huina nui i ka lāʻau lapaʻau ka 5 mg. Aia kekahi mau māhele:

• ʻ stlelo ʻehala
• Mannitol
• ʻO ka lāʻau ʻo Magnesium
• Ka uhi ʻana i ke kukui Opadry.

Nā papa pākuʻi 5 mg o kahi ʻulaʻulaʻula a me nā kihi beveled, ma ka ʻaoʻao hoʻokahi kahi hōʻailona "D5". Hāʻawi ʻia nā pōpoki i kahi māla bluster o 7 mau pcs. Aia i loko o ka pā he 5 mau māmoli.

Hoʻomaopopo i nā waiwai

ʻO ka mea ikaikaʻo Trazhenty kekahi o nā mea pale o ka enzyme dipeptidyl peptidase-4. Ma lalo o ka hopena o kēia mau mea, ʻike ʻia ka luku ʻia o nā hormones infletin, ka mea iā HIP, a me GLP-1 (hāʻawi lākou i ka hoʻoponopono i ke kiʻekiʻe o ke kō).

Hoʻonui pinepine ʻia ka ulu ʻana o nā homoni ma hope o ka ʻaina. Inā ma loko o ke koko he pae maʻamau o ka glucose a i ʻole ka hoʻonui iki ʻia, a laila ma lalo o ka mana o HIP a me GLP-1, ʻike ʻia ka wikiwiki o ka synthesis o ka insulin, ʻoi aku ka maikaʻi i ka huna ʻia e ka pancreas. Eia kekahi, pale ka GLP-1 i ke kaʻina hana o ka hōʻiliʻili o ka glucose i loko o ka ate.

Nā huahana o ka lāʻau Tredent a me ka lāʻau lapaʻau iho e hoʻonui i ke kiʻekiʻe o ka incretins, ma lalo o ka mana o nā lāʻau lapaʻau, kā lākou hana ikaika (hoʻonui i ke synthesis o ka insulin) e nānā.

He mea kūpono ia e hāʻawi nā lāʻau lapaʻau i ka hoʻonui ʻana i ka hana o ka insulin e hilinaʻi ana i ka glucose, ʻoiai e hoʻemi ana i ka hana huna o ka glucogan, ma muli o kēia, e hoʻomaʻamaʻa ka nui o ke kō koko koko.

Trazenta: nā ʻōkuhi piha no ka hoʻohana

Kumukūʻai: mai 1610 a 1987 rubles.

Hoʻomaopopo ʻia e hoʻohana i ka 1 pil i hoʻokahi lā i ka lā. Hiki ke hoʻokau Terzety ma kahi o ka ʻina.

Inā ua nalowale kekahi papa o ka lāʻau lapaʻau hypoglycemic, pono pono ʻoe e lawe koke, e like me kāu e hoʻomanaʻo nei no ka pā. He mea kūpono ia e lawe ʻia he ʻelua kinana o nā lāʻau i ka lā i contraindicated.

ʻAʻole i kau ʻia ka hoʻoponopono ʻia ʻana o nā maʻi me nā maʻi āpau o nā ʻōnaehana renalest, me ke kūpaʻa a me nā mea maʻi a me nā mea maʻi kahiko.

Nā Kūlana a me nā Mākaʻi

ʻAʻole pono nā ʻano maʻi hypoglycemic e:

• ʻAno maʻi type 1
• ʻO nā keiki o ke keiki (ʻo ke keiki ma lalo o 18 makahiki mau makahiki)
• ʻO ka naʻau o ke kumu nui a me nā mea hoʻohui'ē aʻe
• Maʻi molaʻi
• Kekoa, GV.

ʻAʻole i kuhikuhi ʻia ʻo Trazent i nā poʻe me nā hōʻailona o ka ketoacidosis, a me kahi mea i loaʻa i ka insulin i hilinaʻi ʻia o ka maʻi maʻi.

No ka mea e hoʻonāukiuki ʻia nā derivatives sulfonylurea i ka hoʻomohala ʻana o ka hypoglycemia, ua kuhikuhi ʻia nā lāʻau lapaʻau me ka mālama nui loa i ka hihia o ka lawelawe ʻana. Inā kūpono, hoʻemi ʻia ka nui o nā lāʻau lapaʻau.

ʻO ka loaʻa ʻana o ka linagliptin ʻaʻole e hoʻonui i ka maʻi mai ka CCC.

I ka hui pū me nā lāʻau lapaʻau hypoglycemic ʻē aʻe, hiki ke kuhikuhi ʻia a i ʻole ʻo ka hopena kino ʻole.

Ke lawe nei i nā pōpoki ma kahi ʻōpū ʻole, ʻike nui ka nui o ka hemoglobin glycosylated a me ka glucose.

Inā lawe ʻia ka lāʻau lapaʻau e nā poʻe maʻi kahiko, he hōʻemi i ka hemoglobin glycated, ʻoiai ua emi ka nui o ke koko wikiwiki.

ʻAʻole pili ka lāʻau hypoglycemic i ka hoʻonuiʻana o ka puʻuwai cardiovascular.

I kekahi mau hihia, i ka wā o ka mea loea me Trazhenta, hiki ke hoʻopaʻa ʻia i ka hoʻomohala ʻana o ka maʻi pancreatitis. I nā hōʻailona mua o ka maʻi, pono ke hoʻopau i ka komo ʻana o nā papa hypoglycemic a kūkākūkā me kahi kauka.

E pale aku i ke ʻano o ka mālama ʻana, ʻaʻole i hoʻoholo ʻia ʻo ka mahanikala, e pili ana i kēia pili ʻana, pono e mālama ʻia ka mālama kūikawā ma ka holo ʻana i nā hana pono, a me nā kaʻa hoʻi.

Nā pili kūleʻa lāʻau

Me ka hoʻohana pū ʻana o ka ritonavir (ka nui o ka 200 mg), kahi piʻi i AUC a me Cmax o linagliptin pono i nānā ʻia i 2 r. a me 3 p. ia wa. ʻAʻole hiki ke kapa ʻia kēlā mau loli, he kumu kūpono ʻole.

Ke lawe nei i rifampicin, hoʻemi ka nui o nā AUC a me Cmax i ka 40-43%, a me ka emi o ka nānā ʻana i ka hana basal a dipeptidyl peptidase-4 pono e nānā ʻia e ka mea e pili ana iā 40%.

ʻO ka hui kūleʻa ʻana me ka digoxin ʻaʻohe hopena koʻikoʻi ma ka pharmacokinetics o ka mea ikaika.

Hiki i ke Linagliptin ke hana i ka kaʻina o ka metabolic, akā i kahi mea liʻiliʻi. Ke lawe nei i nā lāʻau lapaʻau, ka hoʻololi i ka metabolic o ka mea i hele mai me ka komo o ka pūnaehana CYP3A4, pono ʻoe e hoʻoponopono i ke ʻano o ka Trazhenta.

Nā hopena ʻaoʻao a me ka overdose

I ka wā o Trazhenta, hiki ke mālama i ka ulu ʻana o nā hōʻailona ʻaoʻao, ʻo ia ke ʻano o ka ʻano kikoʻī o ke kino. I kekahi mau manawa, ʻaʻole i ʻike ʻia nā hōʻailona maikaʻi ʻole i ka pōpilikia nui, ʻo ka mea e loaʻa ana i kahi ʻano haʻahaʻa.

Hōʻike ʻia nā hōʻike maikaʻi ʻole:

• Hypoglycemia
• Ke hoʻomau nei o ka pancreatitis
• ʻO ka loaʻa kālā
• Peha a me ka ʻeha koʻikoʻi
• ʻO ka hoʻomakaʻana o nā nasopharyngitis
• ʻO nā ʻeha ma ke ʻano o ka urticaria
• Hono.

I ka hopena o nā kūlana i wehewehe ʻia, pono e nīnau aku i ke kauka no ke aʻo ʻana. I nā hanana ʻinoʻino loa, hoʻopau ʻia ka lāʻau lapaʻau, e koi ʻia ka hoʻokipa.

I kekahi mau manawa, ʻōlelo ke kauka e hoʻohuli iā Trazent me nā analogue.

ʻAʻole i kākau ʻia nā hihia o ka overdose.

Ke lawe nei i nā overdoses o Trazhenta, e nānā ʻia kahi kaʻina hana flrointestinal. Pono ia e nānā i ke kō o ke koko a mālama i ka mālama maʻi hōʻailona ma lalo o ka nānā o kekahi loea.

MSD PHARMACEUTICALS, Netherlands

Kūʻai mai 1465 a 1940 mau rubles.

ʻO Jasonvia - kahi lāʻau lapaʻau e pili ana i ka sitagliptin, hōʻike i ka hopena hypoglycemic i haʻi ʻia. Ua kuhikuhi ʻia no ka mālama ʻana o ka maʻi mellitus type 2 (ʻelua monotherapy a me nā lāʻau lapaʻau i hoʻohui ʻia). Loaʻa i nā palapala papa.

NOHO

• Hiki ke kuhikuhi ʻia i nā poʻe me nā maʻi paleka
• E hoʻokele nei ka hoʻokele pill
• Hiki ke lawe ʻia ia e like me nā meaʻai.

ʻĀpuka:

• ʻO ke kumu kūʻai kiʻekiʻe
• ʻAʻole i kuhikuhi ʻia i nā keiki ma lalo o 18 makahiki
• ʻAʻole pono e hoʻohui pū me ka cyclosporine.

ʻO Novartis Pharma, Switzerland

Kūʻai mai 715 a 1998 ka rub.

Lawe ʻia ka lāʻau lapaʻau e mālama i ka maʻi maʻi (hōʻike o ke ʻano hypoglycemic). ʻO ka mahele nui o Galvus - vildagliptin e pili pono ana i ka pancreas a ke hoʻopaʻa nei i ka peptidase-4 o ka enzyme, ma muli o ia ka emi ʻana o ke kō o ke koko a me ka hoʻoweliweli ʻana i ka huna ʻana i ka insulin. Ua kuhikuhi ʻia ka lāʻau lapaʻau no ka maʻi maʻamau o ka 2, ʻo ke ʻano o ka lāʻau lapaʻau ka hoʻonohonoho ʻokoʻa. ʻO ka palapala puka a Galvus i papa.

NOHO

• Hiki ke hoʻohana ʻia me ka metformin
• Ua hoʻomaopopo ʻia
• Loaʻa kiʻekiʻe bioavailability o ka mea hana - 85%.

ʻĀpuka:

• Contraindicated i ka hāʻule ʻole o ka naʻau
• ʻAʻole pono e hui pū me ka waiʻona
• Hoʻohana maikaʻi ka hoʻomaʻemaʻe wale ʻana me ka meaʻai.

ʻO nā huahana Pharmacodynamic a me nā huahana pharmacokinetic

ʻO Linagliptin kahi mea pale i ka hoʻoliʻi o ka huina DPP-4. Mālama ia i ka hoʻohuli ʻana i nā hormones incretins - GLP-1 a me ISU. ʻO ka enzyme DPP-4 ke pepehi wikiwiki nei i kēia mau hormones. Mālama ka incretins i ka pae o ka physiological o ka kaʻe o ka glucose. ʻOi aku ka haʻahaʻa o GLP-1 a me GUI i ka lā, akā hiki ke hoʻonui ma hope o ka ʻai. Hoʻokomo kēia mau huaʻala i ka biosynthesis insulin a me kāna hana ʻana o ka pancreas i nā pae gula a me ka hoʻokiʻekiʻe kiʻekiʻe. Eia kekahi, hoʻowalewale ʻo GLP i nā ʻōnaehana e pale i ka hana o ka glucose ma o ka ate.

Komo ʻo Linagliptin i kahi pilina hou me DPP-4, e hoʻonui ana i ke kiʻekiʻe o ka incretins a mālama iā lākou i kahi lōʻihi.

Nui! "Hoʻokomo ʻo" Trazhenta "i ka huna ʻana i ka insulin a pale i ka hana ʻana o glucagon, e alakaʻi ana i ke kūpaʻa o ke kō i loko o ke kino.

Mai nā mea e hoʻōla ai, a hiki ke hana ʻino

ʻAno maʻi 2:

• ʻoiai ʻo ka monotherapy no nā poʻe maʻi e loaʻa ʻole i ka glycemia control ma muli o ke kīpē ʻana o ka papaʻai a me ka hana kino, a me ka ʻole hoʻi i ke ahonui i ka metformin a i ʻole hiki ʻole ke hoʻohana me ka maʻi ʻehā.
• me he mea ia o ka hoʻomaʻamaʻa paʻakikī o ka hui pū me ka metformin, kahi derogative sulfonylurea (SM) a i ʻole thiazolidinedione, inā ʻaʻole e hoʻolalelale ʻia e kahi ʻanoʻai a me ka hoʻomaʻamaʻa ʻana, a inā ʻaʻole i hāʻawi ʻia nā mea i luna mai ka hopena maikaʻi e like me ka monotherapy.
• ma ke ʻano he mea ʻekolu o ka mālama ʻana i ka metformin a me SM ma ke ʻano he maikaʻi ʻole nā ​​meaʻai, hoʻomaʻamaʻa ʻana a i ʻole ka hoʻohana ʻana ʻana i kēia mau lāʻau.

Eia nō hoʻi, i ka mālamaʻana o Trazenta diabetes mellitus, ʻae ʻia ka maʻi diabetes.

• insulin
• metformin
• pioglitazone,
• huikaʻi.

ʻAʻole pāpā ʻia ka hoʻohana ʻana i ka lāʻau lapaʻau i nā poʻe i loaʻa i ka:

• ʻAno maʻi type 1
• maʻi maʻamau ketoacidosis,
• hypersensitivity i ka ʻano o "Trazhenty".

Eia kekahi, ʻaʻole pono ka lāʻau lapaʻau e hoʻohana i nā lāʻau lapaʻau:

• keiki na lalo o ʻumikumamāwalu,
• wahine hāpai
• hānai makuahine.

Loaʻa nā hopena ʻaoʻao

ʻO ka hoʻomohala ʻana o nā hopena ʻaoʻao ka mea hilinaʻi nui ia i ka hoʻohana ʻana o Trazenti.

1. I ka wā mononotherapy, ulu ka mea maʻi: hypersensitivity, kōmala, pancreatitis, nasopharyngitis.
2. ʻO ka hui pū me ka metformin e hoʻonāukiuki i ka ulu ʻana o ka hypersensitivity, ka hoʻouka ʻana i ka mare, nasopharyngitis, maʻi pancreatic.
3. Inā hoʻohana ka mea maʻi i ka lāʻau lapaʻau me SM, a laila, i ka hoʻohui aʻe i nā hopena o luna aʻe, e piʻi aʻe ka hopena o ka hoʻomohala ʻana i ka hypertriglyceridemia.
4. ʻO ka hui pū ʻana o "Trazhenty" a me pioglitazone hiki ke hopena i nā hopena o luna, hyperlipidemia a me ka loaʻaʻana o ka paona.
5. Me ka hoʻohana pū ʻana me ka insulin, ua ʻōlelo ʻia nā mea ʻino maikaʻi ʻole a me ka constipation.
6. Ma o ka hoʻohana ʻana ma hope o ka kūʻai ʻana hiki ke hana i ka haʻalulu angioedema, urticaria, rashes, a me ka pancreatitis waha.

ʻO ka papa inoa o nā helu, nā hopena o ka lāʻau overdose

Lawe ʻia nā papa ʻōlelo. Ma ke ʻano he kānāwai, ʻo ka nui o ka lā he 5 mg. Inā hoʻopau ka mea maʻi iā lākou me ka metformin, e like nō ka kaʻe o nā mea hope.

Hiki ke hoʻohana ʻia "Trazhentu" me nā manaʻo ʻole o ka meaʻai.

Inā poina e ka mea maʻi hānai e lawe i ka lāʻau lapaʻau, pono ia e hana koke iā ia, akā ʻaʻole iʻoi aku i mua o ka lāʻau i ʻōlelo ʻia ʻia.

ʻAʻole pono ʻo Renal i ka hoʻoponopono lōkahi o Trazenti.

Hiki i ka maʻi maʻi me ke ʻano hepatic impaired hiki ke lawe i kahi hopena ʻono ʻokoʻa, akā pono lākou ma lalo o ka mālama mālama olakino maʻamau.

Ua hōʻike ʻia nā haʻawina ʻoi aku ka ʻoi aku o ka dosage i kēlā me kēia lā ma mua o 120 mau manawa, ʻo ia ka lawe ʻana o 600 mg o ka lāʻau lapaʻau ʻaʻole i hoʻonāukiuki i ka maikaʻi o ka poʻe olakino.

Inā hele ka maʻa ma ka maʻi ma muli o ka nui o ke kō, pono ia:

• hoʻihoʻi i ke koena lāʻau lapaʻau mai ke kaʻe o ka digestive,
• ua hele i kahi hoʻokolohua maʻi
• hoʻohana i ka hana hōʻailona.

Nui! Pono kekahi mea loea kūpono e hoʻoholo i ka lōʻihi e hiki i ka mea maʻi ke lawe i ka "Trazhenta" me ke kāpae ʻole.

E hui pū me nā lāʻau lapaʻau ʻē aʻe

ʻO ka hoʻokele kaulele o Trazhenta me Metformin, ʻoiai me ka pauku nui loa, ʻaʻole ia i hoʻonāukiuki i nā loli nui i ka wai lāʻau lapaʻau o nā lāʻau lapaʻau ʻelua.

ʻO ka hoʻokele maʻalahi ʻana me "Pioglitazone" ʻaʻole ia e pili i ke ʻano lāʻau lapaʻau o nā lāʻau ʻelua.

Hiki ke hoʻohana ʻia "Trazhenta" i hui pū me "Glibenkamid", akā i kēia hana wale ka hoʻemi ʻana o ka manaʻo kiʻekiʻe o nā mea hope loa. ʻO nā mea'ē aʻe me ka sulfinyl urea e loaʻa like nā hōʻailona like.

ʻO ka hui pūʻana o "Trazhenty" me "Rifampiin" hoʻemi i ka neʻe o ka mea mua. Mālama ʻia nā waiwai pharmacological i kahi liʻiliʻi, akā ʻaʻole 100 mau loiloi e lilo.

Hiki iā ʻoe ke lawe iā Digoxin i ka manawa like e like me Trazenta. ʻO kēlā hui like ʻole e pili i ka waiwai o ka pharmacokinetic o kēia mau lāʻau lapaʻau. ʻO kahi kaʻina hana e like me ka hui pū ʻana o ka linagliptin a me Warfarin.

Kekahi mau hewa kekahi i hoʻopaʻa ʻia me ka hoʻomohala pinepine ʻana o ka linagliptin a me Simvastatin.

Ke hoʻohana ʻana ʻo Transit, hiki i ka maʻi maʻi ke hoʻohana ʻĀ.

Nā kuʻi a me ka ʻano like o ka lāʻau

Inā ʻaʻole hiki i ka mea maʻi hapanui ke lawe iā Trazent no kekahi mau kumu, hiki ke kuhikuhi ʻia nā mea paʻa.

Nā ʻōlelo kikoʻī

ʻAi ʻia ka "Trazent" no ka koho ʻana no ka T1DM a me ka ketoacidosis (ma hope aʻe o T1DM).

Ua hōʻike ʻia nā noiʻi mana i ka hypoglycemia i ka wā e hoʻohana ai i nā hui lapaʻau, ʻaʻole i lawe ʻia e Transjet, akā e nā metformin a me nā huaʻōlelo thiazolidinedione, a i ʻole nā ​​mea huakaʻi sulfinyl urea. Me kahi kiʻekiʻe kiʻekiʻe o ka hypoglycemia, pono ke hoʻoponopono ʻia i ka hala o nā mea hope.

ʻAʻole hiki iā Linagliptin ke kumu e hoʻokō ai i ka pathology CCC. I ka hui pū me nā mea lapaʻau ʻē aʻe, hiki ke kuhikuhi ʻia i nā poʻe maʻi e loaʻa ana i ka hana renal impaired.

I kekahi mau maʻi maʻi, ua hoʻonāukiuki ka lāʻau lapaʻau i ka pancreatitis aʻokiʻoki. I kāna mau hōʻailona mua (ka ʻeha o ka ʻōpū, nā pilikia ʻeha a me ka nāwaliwali maʻamau), pono i kahi maʻi maʻi maʻi e hoʻomaha i ka hoʻohana ʻana iā Trazenti a kūkā koke i kahi kauka.

Ma kēia manawa, ʻaʻohe ʻikepili e pili ana i ka hopena o ka lāʻau lapaʻau ma ka hiki o kahi maʻi maʻi maʻi e kāohi i nā ʻano like ʻole. Akā ʻo ka mea pono e loaʻa i ka mea maʻi i nā pilikia koikoi, inu i ka lāʻau lapaʻau ma mua o nā kūlana e koi ai i ka hopena wikiwiki a me ka neʻe pono ʻana.

Hoʻohana ka hapanui o nā maʻi maʻi i ka lāʻau ma ke ʻano o ka lāʻau paʻakikī, no laila he paʻakikī nui ka hoʻoholo ʻana i kona pono. Akā ma ka Pūnaewele ma nā pūnaewele ʻike kūikawā a me nā ʻatikala, hiki iā ʻoe ke loaʻa nā loiloi e pili ana i kēia lāʻau lapaʻau. Ma ka laulā nui, he kūpono lākou.

Ua hōʻike wau ma ka pale ʻana i ka insulin. No ka hoʻomaikaʻi maikaʻi maikaʻi, ua hoʻohana wau i nā lāʻau lapaʻau i loko o nā ʻāina a me nā ʻāina ʻē no ka manawa lōʻihi, akā ʻaʻohe hopena maikaʻi. Ua ʻōlelo ke kauka i "Trazhent", inu wau ia mea no hoʻokahi mahina, me ka hahai ʻana i ka ʻai koʻikoʻi. I kēia manawa pōkole, nalowale wau i ka 4,5 kileman. Ka hauʻoli loa i ka hopena. I ka hoʻomaka ʻana o ka lawe ʻana i ka lāʻau lapaʻau aia kahi liʻiliʻi liʻiliʻi e haʻi ʻia i ka wehewehe ʻana i nā papa, akā hele koke lākou.

Hoʻomaka koʻu kakahiaka ma ka lawe ʻana i ka paila "Diabeton", i ke ahiahi inu au i ka "Trazhentu". Hōʻike ka waihona hilo i 6-8 mmol / L. ʻOiai he maʻi maʻi maʻi wau me ka ʻike, noʻu he hopena maikaʻi loa kēia. Ke ʻole ʻo Trazhenta, ʻaʻole i hāʻule ka kuhikuhi hemoglobin glycated ma lalo o 9.3 pakeneka, eia kēia ke 6.4. Hoʻopili i kahi maʻi maʻi, ua maʻi wau i ka pyelonephritis, akā ʻaʻole i hoʻonāukiuki ʻo Trazhenta i nā keiki. ʻOiai he mea kūʻai nui kēia mau penikala no kahi penikala, ʻo kā lākou hopena e hoʻokō ai i nā manaʻolana āpau.

ʻO Petr Mikhailovich, 65 makahiki

Ua kuhikuhi ke kauka i "Trazhenta" e hoʻopaʻa i ka paona a me ke kō. I nā lā mua o ka hoʻohana ʻana i nā lāʻau lapaʻau, hōʻike ikaika nā hopena ʻaoʻao. I noi au e ʻimi i kahi kikoʻī. ʻAe, kūʻai nui ʻia kēia "Trazhenta".

ʻO ka kumukūʻai o nā lāʻau lapaʻau i nā lāʻau lapaʻau e like me 1480 a 1820 mau rubles no ka hoʻopiʻi helu 30. "Kūʻai akuʻo" Trazhenta "i kahi lāʻau lapaʻau i nā mea lapaʻau.

ʻO ka hui o DPP-4 inhibitors, kahi iā Trazhenta, ua hōʻike i ka hopena antidiabetic a me ka palekana. ʻAʻole hoʻonāukiuki ia mau lāʻau lapaʻau i ka hopena hypoglycemic, ʻaʻole e hoʻoikaika i ka loaʻa ʻana o ka paona a ʻaʻole i hopena maikaʻi ʻole e kau ai nā kau. Ma kēia manawa, ke manaʻo nei kēia hui āpau o nā lāʻau lapaʻau ʻoi loa ka maikaʻi a me ka hoʻohiki ʻana i ka hopena o ka mana o T2DM